{"id":2322,"date":"2022-09-21T10:04:44","date_gmt":"2022-09-21T10:04:44","guid":{"rendered":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/?p=2322"},"modified":"2023-02-14T10:08:20","modified_gmt":"2023-02-14T10:08:20","slug":"inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle","status":"publish","type":"post","link":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/","title":{"rendered":"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Is the FDA adapting to cell therapies ? How ? Why and how cell therapy differ from small molecules ? A quick overview with Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Transcript:<\/b><\/p>

\u00a0<\/p>

Cell therapy it’s much more modular. Because you know, when we design a CAR, the CAR has several different components. And if we change any component, we have to open a new IND and that takes a long time. So now the FDA has a system set up that will potentially let you do kind of an umbrella protocol. Where you still need to submit all of the required data for each of your variations on the theme. So you might have a CAR recognizing a certain antigen.<\/p>

And then you might have the same CAR with some kind of armament or you know armament A, armament B. And you might be able to study them all in one clinical protocol under kind of a nested IND.<\/p>

So that would certainly optimize our approach here. Because otherwise it’s very laborious to obtain an entirely new IND for a very similar therapy. And that problem really hasn’t existed before of course the regulatory structure we have is largely developed in response to small molecule and then more lately monoclonal antibody therapy. And in those cases, it wasn’t generally like if you change even a single atom on a small molecule you can end up with a very different small molecule so it wasn’t modular in the way that’s for cell therapy. And even if you don’t change the CAR, changing the manufacturing protocol -and there’s\u00a0some innovation there – so you know that traditional CAR-T autologous manufacturing protocol is 9 to\u00a011 days. Novartis is now publishing,
showing some data conferences from its T-Charge platform which is only two days.<\/p>

And U. Penn recently published a one-day protocol. So those would have a quite a large impact on… The process is the product, pretty much for living cells. So even if you don’t change anything genetically about your therapy, changing the process can have a big impact. And being able to do that efficiently without having to undergo the full IND process for every incremental change, I think could be important.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tWATCH FULL VIDEO<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Is the FDA adapting to cell therapies ? How ? Why and how cell therapy differ from small molecules ? A quick overview with Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania<\/p>\n","protected":false},"author":1,"featured_media":2324,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"aioseo_notices":[],"yoast_head":"\nINDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Is the FDA adapting to cell therapies ? How ? Why and how cell therapy differ from small molecules ? A quick overview with Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania\" \/>\n<meta property=\"og:url\" content=\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/\" \/>\n<meta property=\"og:site_name\" content=\"Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T10:04:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-14T10:08:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-content\/uploads\/sites\/5\/2023\/09\/miniature-T5-ok-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Piergueritona\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@treefrogtx\" \/>\n<meta name=\"twitter:site\" content=\"@treefrogtx\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/\"},\"author\":{\"name\":\"Piergueritona\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\"},\"headline\":\"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle\",\"datePublished\":\"2022-09-21T10:04:44+00:00\",\"dateModified\":\"2023-02-14T10:08:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#organization\"},\"articleSection\":[\"Videos\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/\",\"url\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/\",\"name\":\"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#website\"},\"datePublished\":\"2022-09-21T10:04:44+00:00\",\"dateModified\":\"2023-02-14T10:08:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#website\",\"url\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/\",\"name\":\"Stem Cells and Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics\",\"description\":\"In The Stem Cell Jungle Blog\",\"publisher\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#organization\",\"name\":\"Stem Cells and Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics\",\"url\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-content\/uploads\/sites\/5\/2022\/09\/t2Dmvts8-Copie.png\",\"contentUrl\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-content\/uploads\/sites\/5\/2022\/09\/t2Dmvts8-Copie.png\",\"width\":686,\"height\":607,\"caption\":\"Stem Cells and Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics\"},\"image\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/twitter.com\/treefrogtx\",\"https:\/\/www.linkedin.com\/company\/treefrog-therapeutics\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\",\"name\":\"Piergueritona\",\"sameAs\":[\"https:\/\/preprod.treefrog.fr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics","og_description":"Is the FDA adapting to cell therapies ? How ? Why and how cell therapy differ from small molecules ? A quick overview with Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania","og_url":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/","og_site_name":"Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics","article_published_time":"2022-09-21T10:04:44+00:00","article_modified_time":"2023-02-14T10:08:20+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-content\/uploads\/sites\/5\/2023\/09\/miniature-T5-ok-scaled.jpg","type":"image\/jpeg"}],"author":"Piergueritona","twitter_card":"summary_large_image","twitter_creator":"@treefrogtx","twitter_site":"@treefrogtx","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#article","isPartOf":{"@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/"},"author":{"name":"Piergueritona","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220"},"headline":"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle","datePublished":"2022-09-21T10:04:44+00:00","dateModified":"2023-02-14T10:08:20+00:00","mainEntityOfPage":{"@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#organization"},"articleSection":["Videos"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/","url":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/","name":"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics","isPartOf":{"@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#website"},"datePublished":"2022-09-21T10:04:44+00:00","dateModified":"2023-02-14T10:08:20+00:00","breadcrumb":{"@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/inds-in-immuno-oncology-accommodating-changes-in-car-constructs-or-manufacturing-process-neil-sheppard-stem-cell-jungle\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/"},{"@type":"ListItem","position":2,"name":"INDs in immuno-oncology : accommodating changes in CAR constructs or manufacturing process | Neil Sheppard | Stem Cell Jungle"}]},{"@type":"WebSite","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#website","url":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/","name":"Stem Cells and Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics","description":"In The Stem Cell Jungle Blog","publisher":{"@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#organization","name":"Stem Cells and Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics","url":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/logo\/image\/","url":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-content\/uploads\/sites\/5\/2022\/09\/t2Dmvts8-Copie.png","contentUrl":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-content\/uploads\/sites\/5\/2022\/09\/t2Dmvts8-Copie.png","width":686,"height":607,"caption":"Stem Cells and Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics"},"image":{"@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/twitter.com\/treefrogtx","https:\/\/www.linkedin.com\/company\/treefrog-therapeutics\/"]},{"@type":"Person","@id":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220","name":"Piergueritona","sameAs":["https:\/\/preprod.treefrog.fr"]}]}},"_links":{"self":[{"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/posts\/2322"}],"collection":[{"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/comments?post=2322"}],"version-history":[{"count":8,"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/posts\/2322\/revisions"}],"predecessor-version":[{"id":2331,"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/posts\/2322\/revisions\/2331"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/media\/2324"}],"wp:attachment":[{"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/media?parent=2322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/categories?post=2322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/stemcelljungle\/wp-json\/wp\/v2\/tags?post=2322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}